Main Conference: September 23-25, 2026 | Boston, MA
Main Conference Track: Development of Emerging Cell & Gene Therapies
Deep dive into the breakthroughs shaping the next era of advanced therapies
Engineering the Next Wave of Cell & Gene Therapies
Blurb: The Development of Emerging Cell and Gene Therapies track is a 2-day deep dive into the next generation of cell and gene therapies expanding beyond rare diseases into solid tumours and larger patient populations. This track delivers real-world case studies on scaling in vivo CAR-T therapies, AI-driven product design, disruptive targeted delivery technologies, and leveraging gene editing tools for in vivo delivery and applications beyond the liver, enhancing precision and therapeutic potential. Hear from industry pioneers on next-generation non-viral delivery systems and scalable solutions that are redefining the future of cell and gene therapies.
Session Spotlight: In Vivo Therapies: From Concept to Reality
Keynote: Programming Immunity In Vivo: Targeted RNA–LNP Platforms for Precision CAR Engineering
Friday, September 25th 2026 09:30am
Robert Hofmeister, Chief Scientific Officer at CREATE Medicines
This keynote presentation explores how CREATE Medicines is developing in vivo CAR therapies using targeted mRNA–LNP delivery to program immune cells directly in patients. By combining modular CAR design with optimized RNA architectures, the platform enables durable, controlled expression across T cells and innate compartments. Preclinical and clinical data demonstrate robust activity of in vivo engineered CAR-T cells, supporting scalable, off-the-shelf immunotherapies for autoimmune diseases and cancer.
Track Themes: Building the Future - A CGT Development Blueprint
Navigating the Road Ahead for In Vivo CAR-T
Explore critical product development, clinical advances, scale-up, delivery, and manufacturing strategies for in vivo CAR-T therapies, addressing production challenges, regulatory considerations, and the future potential of this transformative approach.
Targeted Delivery & Gene Editing
Go beyond viral vectors and explore the manufacturing and CMC challenges for in vivo gene editing and LNP-based delivery systems enabling enhanced efficiency, precision, and therapeutic reach beyond hepatic targets.
Starting with the End in Mind
Uncover strategic approaches to designing smart scalable, phase-appropriate CGT manufacturing processes that balance early-stage flexibility with long-term commercial viability, regulatory compliance, and broad patient access.
R&D Innovations
Discover cutting-edge R&D developments including, in vivo CAR-T, solid tumours, and new therapeutic modalities expanding treatments to broader populations.